Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1675.708 - 1696.927 Dr. Bogdana Schmidt

From a cup now at the NIH, this may be less of a point for you guys, but let's say a patient refuses adjuvant chemo at this point. Are you able to offer them checkpoint inhibitor in lieu of it? Oh, yes, of course. Because I know that some folks will say that they can't get insurance approval for it if they're CIS eligible. But obviously, at the NIH, this is less of an issue.